Janux therapeutics, inc.JANX.US Overview
JANX Overall Performance
JANX AI Analysis & Strategy
JANX Recent Performance
0.18%
Janux therapeutics, inc.
1.30%
Avg of Sector
0.61%
S&P500
JANX PowerScanner
JANX Key Information
JANX Valuation Metrics
JANX Earnings Table
JANX Profile
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.